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Abstract
Antisense oligonucleotides (AOs) have been shown to induce dystrophin expression in muscles
cells of patients with Duchenne Muscular Dystrophy (DMD) and in the mdx mouse, the murine
model of DMD. However, ineffective delivery of AOs limits their therapeutic potential.
Copolymers of cationic poly(ethylene imine) (PEI) and non-ionic poly(ethylene glycol) (PEG) form
stable nanoparticles when complexed with AOs, but the positive surface charge on the resultant
PEG-PEI-AO nanoparticles limits their biodistribution. We adapted a modified double emulsion
procedure for encapsulating PEG-PEI-AO polyplexes into degradable polylactide-co-glycolic acid
(PLGA) nanospheres. Formulation parameters were varied including PLGA molecular weight, ester
end-capping, and sonication energy/volume. Our results showed successful encapsulation of PEG-
PEI-AO within PLGA nanospheres with average diameters ranging from 215 to 240 nm.
Encapsulation efficiency ranged from 60 to 100%, and zeta potential measurements confirmed
shielding of the PEG-PEI-AO cationic charge. Kinetic measurements of 17 kDa PLGA showed a
rapid burst release of about 20% of the PEG-PEI-AO, followed by sustained release of up to 65%
over three weeks. To evaluate functionality, PEG-PEI-AO polyplexes were loaded into PLGA
nanospheres using an AO that is known to induce dystrophin expression in dystrophic mdx mice.
Intramuscular injections of this compound into mdx mice resulted in over 300 dystrophin-positive
muscle fibers distributed throughout the muscle cross-sections, approximately 3.4 times greater
than for injections of AO alone. We conclude that PLGA nanospheres are effective compounds for
the sustained release of PEG-PEI-AO polyplexes in skeletal muscle and concomitant expression of
dystrophin, and may have translational potential in treating DMD.
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Steric block antisense oligonucleotides (AOs) are consid-
ered potential therapeutics for a variety of diseases due to
their capacity to modulate alternative splicing, correct aber-
rant mRNA splicing, and induce exon skipping [1-5]. Duch-
enne muscular dystrophy (DMD), a fatal disease caused by
mutations in the gene encoding dystrophin, has been
established as an excellent candidate for AO-based treat-
ment [6-9]. The main barrier that has limited the usefulness
of AOs in treatment of DMD, and most other diseases, is
the inability to deliver them to their target cell nuclei.
Poly(ethylene imine) (PEI) is a highly protonatable amine
rich polymer that has been established as an efficient nucle-
otide carrier [10]. The cationic nature of PEI allows the poly-
mer to interact with both the negatively-charged phosphate
backbone of nucleotides and the negatively-charged ele-
ments of cell membranes, promoting endocytotic uptake of
the nucleotides into cells [10-17]. Grafting of polyethylene
glycol (PEG) polymers to PEI has been shown to signifi-
cantly enhance its functionality as a nucleotide carrier by
reducing cytotoxicity and improving biocompatibility [13-
15,18]. Overall, PEG-PEI copolymers represent an adaptable
nucleotide delivery system with controllable size and surface
charge, and flexibility for addition of moieties that target spe-
cific entities on cell membranes.
Cationic PEI-based transfection agents have repeatedly
been demonstrated to be one of the most effective non-
viral vectors for facilitating uptake of nucleic acid based
Characterization of 72 kDa lauryl ester end-capped PLGA nanospheres with and without encapsulated PEG-PEI-AO polyplexes or AO aloneFigure 1
Characterization of 72 kDa lauryl ester end-capped PLGA nanospheres with and without encapsulated PEG-
PEI-AO polyplexes or AO alone. (A) Mean diameter determined by DLS. PLGA nanospheres loaded with PEG-PEI-AO 
polyplex were significantly larger than those loaded with AO alone or unloaded samples (*P = .0079). (B) Polymer yields calcu-
lated based on the weight of the resultant nanospheres and initial mass of PLGA and encapsulant. (C) Encapsulation efficiency 
(EE). Three separate samples were evaluated for each group.Page 2 of 12
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effect [10,16,19-21]. However, although PEG-PEI copoly-
mers have been demonstrated to facilitate delivery of AOs
in vivo, [22-25], the cationic surface charge of polyplexes
which enables cellular uptake, likely limits their biodistri-
bution by non-specific binding to components in the
blood and extracellular environment [26,27]. Methods of
shielding the cationic surface charge of polyplexes, fol-
lowed by sustained release, could overcome these limita-
tions.
Biodegradable poly(lactic-co-glycolic acid) (PLGA) poly-
mers are versatile and biocompatible compounds that
have been FDA approved and utilized in a wide variety of
drug delivery applications including the encapsulation of
nucleic acids [28-30]. The properties of PLGA nano-
spheres can be controlled by utilizing a range of PLGA
chemistries and altering the nanosphere synthesis condi-
tions, producing nanospheres with variable release kinet-
ics and sizes [28,30-32]. Nanosized PLGA has been
formulated for encapsulation of naked plasmid DNA and
AO [33,34]. Also, PEI has been successfully encapsulated
into PLGA nanospheres for intranasal delivery of genes to
pulmonary epithelial cells [35], and oral delivery of oligo-
nucletides as an immunostimulant [36], or simply to
improve in vitro transfection efficiency [37,38]. Previ-
ously, cationic polymers (PEI or polylysine) complexed
with nucleic acids have been encapsulated into PLGA,
however most of these compounds were restricted to
micron sized spheres [39-44]. For many drug delivery
applications however, it would be preferential to encapsu-
late PEI within nanosized spheres. Nanoparticles may be
preferred over microparticles as delivery vehicles due to
more favorable circulation times as well as biodistribu-
tion. Small nanoparticles which can be internalized
within cells are also useful for cytosolic delivery of com-
pounds that cannot readily cross cell membranes, such as
nucleic acids [45]. Recently, one study has demonstrated
the encapsulation of PEI within PLGA nanospheres,
showing some improvement in transfection efficiency
and cell viability, however, this study is limited to cul-
tured cells [46].
Presently we studied formulation parameters for the
encapsulation of PEG-PEI-AO polyplexes within PLGA
nanospheres, and demonstrated their functionality in
Influence of sonication intensity and vessel volume on the mean size and size distribution of unloaded 72 kDa lauryl ester end-capp d PLGA anospheresFigure 2
Influence of sonication intensity and vessel volume on the mean size and size distribution of unloaded 72 kDa 
lauryl ester end-capped PLGA nanospheres. (A) Mean diameter determined by DLS is shown for the nanospheres pre-
pared in either a high or low volume chamber and with either low intensity (38 W) or high intensity (52 W) sonication. Three 
separate samples were evaluated for each group. (B) Size distribution based on the DLS measurements is shown for a single 
sample from each of the groups in panel A. Smaller and more uniform nanospheres were obtained using high sonication inten-
sity in a low volume chamber.Page 3 of 12
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PLGA nanospheres, effectively shielding the cationic sur-
face charge of the polyplexes, and permitting their sus-
tained release. Injections of PEG-PEI-AO encapsulated
into PLGA nanospheres in limb musculature of mdx mice
resulted in improvement in number of dystrophin-posi-
tive fibers compared to AO alone. The results of this
proof-of-concept study demonstrate the feasibility of
encapsulating PEG-PEI-AO polyplexes within PLGA
nanospheres, which may potentially be used for sustained
release of the polyplexes over time or improving the effi-
ciency of systemic polyplex delivery. These compounds
represent promising agents for delivery of AO to dys-
trophic skeletal muscle and may find usage in treatment
of DMD.
Methods
Synthesis of PEG-PEI copolymers
Details of the synthesis of the PEG-PEI copolymers, as
well their physicochemical properties when complexed
with AO were previously described [47]. Briefly, copoly-
mers composed of branched poly(ethylene imine)-25000
(PEI25K) and methoxypoly(ethylene glycol)-5000
(mPEG5K) (Sigma-Aldrich, St. Louis, MO, USA) were pre-
pared using a two-step procedure [13]. First, mPEG5K was
activated with hexane-1,6-diisocyanate. Second, PEI25K
and activated mPEG5K were reacted at a PEG:PEI molar
ratio of 10:1. Throughout the manuscript we refer to this
PEI25K(PEG5K)10copolymer simply as PEG-PEI.
Synthesis of PLGA nanospheres containing PEG-PEI-AO 
polyplexes
Encapsulation of PEG-PEI-AO polyplexes into PLGA
nanospheres was carried out using a double emulsifica-
tion (water-in-oil-in water) technique [48]. PLGA poly-
mers of 72, 50, and 17 kDa were used (all 50:50;
Lakeshore Biomaterials, Birmingham, AL, USA). The 72
kDa PLGA was lauryl ester end-capped, while the other
MWs were not. PLGA (70 mg) was dissolved in 2 mL chlo-
roform (Sigma Aldrich) to form the organic phase, and
then sonicated on ice for 30 seconds at 51 Watts with a
microtip attachment (Ultrasonics W-385 Sonicator; Heat
Systems, Farmingdale, NY, USA). PEG-PEI-AO polyplexes
were prepared by mixing PEG-PEI with a 2'O-methyl AO
('5-GGCCAAACCUCGGCUUACCU-3'; Trilink Biotech-
nologies, San Diego, CA) at a nitrogen to phosphate (N:P)
ratio of 5:1, as previously described [47]. The primary
aqueous phase contained either PEG-PEI-AO (1 mg of
AO), AO alone (1 mg), or only distilled and deionized
water (DI H2O) in a volume of 300 μl. The primary aque-
ous phase was then added to the organic phase, and emul-
sified by sonication for 30 seconds at 30–52 Watts on ice.
The resultant water-in-oil emulsification was added drop-
wise into a 25 mL solution of cold (4°C) 5% polyvinyl
alcohol (22 kDa, 88% Hydrolyzed; Acros Chemicals; Mor-
ris Plains NJ) in a 50 mL glass beaker while stirring at 400
rpm to form the secondary emulsion. In the initial sam-
ples, the secondary emulsion was sonicated for 1 minute
on ice at either 38 W or 52 W. Nanospheres with a smaller
mean size and more uniform size distribution were subse-
quently obtained by splitting the secondary emulsion into
equal volumes in three 20 mL glass scintillation vials, son-
icating each for 1 minute at 52 W on ice, and recombining
the solutions. Chloroform was removed by evaporation
overnight at room temperature while stirring at 400 rpm.
The resultant nanoparticles were collected by high speed
ultracentrifugation (Ultra 80 Ultracentrifuge; Sorvall,
Asheville, NC, USA) at 20000 rpm using an AH-627 rotor
(Sorvall) and appropriate buckets (53,300 g). Particles
were washed twice with DI H2O and collected. The nano-
spheres were then resuspended in DI H2O, and lyophi-
lized for 72 hours (Virtis Gardiner, NY, USA) prior to
storage at -20°C.
Particle size and surface charge
PLGA nanospheres were suspended in a diluted PBS solu-
tion (1× PBS diluted 1:800 in DI H2O, adjusted to pH
7.2). The nanospheres were suspended at a concentration
of 0.1 mg/ml in the diluted PBS solution. Particle size and
surface charge were measured by dynamic light scattering
(DLS) and zeta potential, respectively (Zetasizer; Malvern
Instruments, Southborough, MA, USA). All measure-
ments were made in triplicate.
Encapsulation efficiency and release kinetics
The amount of AO encapsulated within PLGA nano-
spheres (encapsulation efficiency; EE) was determined by
spectrophotometry. PLGA nanospheres encapsulated
with PEG-PEI-AO (1 mg AO) were dissolved in 500 μL of
0.5 M NaOH to release the encapsulant, centrifuged for 30
minutes at 16,000 g (5415D; Eppindorf, Westbury, NY.
USA), and the absorbance of the supernatant was meas-
ured at 260 nm using a low volume quartz cuvette
(Ultraspec 2100; Amersham Biosciences, Piscataway, NJ,
USA). The concentration of AO in the PLGA samples was
determined by comparison with a standard curve gener-
ated from AO at varying concentrations dissolved in 0.5 M
NaOH.
To determine release kinetics, PLGA nanospheres encap-
sulated with PEG-PEI-AO were suspended in sterile PBS (1
mg/ml; pH 7.2) and incubated while rotating at 37°C. At
the desired time points, samples were centrifuged for 30
minutes at 16 g, the supernatant was discarded, and the
pellet was dissolved in 0.5 M NaOH. AO concentration
was measured as described for EE. Both EE and release
kinetics measurements were made in triplicate.
Intramuscular injections of mdx mice
All experiments were performed on male mdx mice 6–8
wks of age (C57BL/10ScSn-Dmdmdx/J) or age-matched
normal male mice (C57BL/10SnJ) (Jackson Laboratories,Page 4 of 12
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mine/xylazine and monitored according to approved NIH
and university guidelines. Tibialis anterior (TA) muscles
(N = 4 per group) were injected with either PLGA-PEG-
PEI-AO, PEG-PEI-AO or AO alone dissolved in 15 μl of
sterile saline as previously described [24,25]. For all
groups the AO dose was 5 μg per injection. After recovery
from anesthesia, mice were returned to normal cage activ-
ity. All treated mice received injections on day 0, 3, and 6
and TA muscles were harvested 3 weeks after the initial
injection. Muscles were isolated, pinned to parafilm-cov-
ered cork, snap frozen in liquid N2-cooled 2-methylbu-
tane, and stored at -80°C until further processing. Control
muscles were harvested from uninjected age-matched mdx
and normal mice.
Immunohistochemistry and histology
Transverse frozen sections (10 μm) were obtained from
TA muscles using a cryostat (Leica CM 3050 S, Bannock-
burn, IL, USA). Dystrophin immunolabeling was per-
formed on frozen sections using a rabbit polyclonal anti-
dystrophin antibody, (1:125; Abcam Inc., Cambridge,
MA, USA), which labels the C-terminus of dystrophin.
The secondary antibody was Cy3-Anti-Rabbit IgG (1:500;
Jackson Immuno Research). Immunosections were coun-
terstained with Hoechst dye (Sigma) to visualize nuclei.
Routine hemotoxylin and eosin (H & E) staining was used
to examine overall muscle morphology and assess the
level of infiltrating mononucleated cells.
Dystrophin-immunolabeled transverse sections obtained
from the midpoint along the length of TA muscles were
imaged as whole sections using a color imaging camera
(SPOT RT; Diagnostic Instruments, Sterling Heights, MI,
USA) mounted on an MZFL3 stereomicroscope (Leica).
The number of dystrophin-positive fibers in entire muscle
cross-sections was counted using the cell counter function
of ImageJ software http://rsb.info.nih.gov/ij/plugins/cell-
counter.html.
Statistical Analysis
All data are reported as mean values ± SEM. Statistical dif-
ferences between treatment groups were evaluated by
ANOVA (Statview; SAS Institute, Cary, NC).
Results and discussion
The goal of this study was to evaluate the feasibility of
encapsulating PEG-PEI-AO polyplexes within biodegrada-
Influence of sonication intensity and vessel volume on the size of 72 kDa lauryl ester end-capped nanospheres encapsulated with PEG-PEI-AO p lyplexFigure 3
Influence of sonication intensity and vessel volume on the size of 72 kDa lauryl ester end-capped nanospheres 
encapsulated with PEG-PEI-AO polyplex. The size distribution within a single prepared sample of nanospheres formu-
lated in a high volume chamber with a low intensity (38 W) sonication (full line) and a low volume chamber with a high intensity 
(51 W) sonication (broken line) were determined using DLS. Polyplex loaded nanospheres formulated with a low volume 
chamber and a high sonication intensity show a more uniform size distribution and smaller mean size.Page 5 of 12
(page number not for citation purposes)
Journal of Nanobiotechnology 2009, 7:1 http://www.jnanobiotechnology.com/content/7/1/1ble PLGA nanospheres for the purpose of improving
delivery of these cationic polyplexes in vivo. We initially
used a double emulsion procedure as outlined by Cohen-
Sacks et. al., [48] to encapsulate either PEG-PEI-AO, AO
alone, or water (unloaded) into 72 kDa ester end-capped
PLGA. DLS measurements showed both AO-loaded and
unloaded PLGA nanospheres had nearly the same size
(292.5 ± 3.1 and 294.9 ± 2.4 nm, respectively; Figure 1A),
and were similar in size to previously reported nano-
spheres loaded with naked phosphorothioated AO [48].
However, nanospheres loaded with PEG-PEI-AO poly-
plexes showed significantly higher mean diameters (345.4
± 28.4 nm) compared to unloaded nanospheres (P <
0.01). This result is consistent with De Rosa et al [39,49]
who observed a marked size increase in micron-sized
PLGA when PEI-AO polyplexes were introduced into the
primary aqueous phase of the emulsion. The average yield
for PLGA nanospheres loaded with PEG-PEI-AO, AO, or
unloaded was 71.0 ± 10.5%, 68.5 ± 10.8%, and 64.5 ±
15.10%, respectively, with no significant difference
Effect of PLGA polymer composition on the properties of resultant nanospheresFigure 4
Effect of PLGA polymer composition on the properties of resultant nanospheres. PLGA (50:50) at molecular 
weights of 72 kDa, 50 kDa, and 17 kDa was used to encapsulate AO. The 50 kDa and 17 kDa polymers did not have lauryl 
ester end groups but unmodified carboxylic acid end groups instead. Measurements were done on unloaded and PEG-PEI-AO 
polyplex loaded nanospheres. The following properties of the nanospheres were evaluated: (A) Mean diameters measured by 
DLS. No statistical difference was observed between the nanospheres formulated using the three different PLGA polymers for 
either loaded or unloaded nanospheres (P > 0.05). (B) Surface charge (evaluated by zeta potential analysis) was determined by 
light scattering. A significant difference in zeta potential was seen between nanospheres formulated using each of the three dif-
ferent PLGA polymers for both polyplex loaded and unloaded nanospheres (P < 0.05). A significantly less negative zeta poten-
tial was observed for polyplex loaded compared to unloaded nanopsheres formulated using 72 kDa endcapped PLGA (*P = 
0.027). No difference in zeta potentials were seen between polyplex loaded and unloaded groups for 50 kDa and 17 kDa 
PLGA. (C) Encapsulation efficiency (EE) of unloaded nanospheres and PEG-PEI-AO loaded nanospheres. Non-endcapped 50 
kDa and 17 kDa PLGA polymers showed significantly higher encapsulation efficiencies compared to endcapped 72 kDa PLGA 
(**P < 0.05). (D) Polymer yield for the unloaded nanospheres and PEG-PEI-AO loaded nanospheres. The yield for 72 kDa 
PLGA was moderately higher than for 50 kDa and 17 kDa PLGA polymers for both unloaded and loaded samples (***P < 0.05). 
All measurements were repeated in triplicate from independently prepared samples.Page 6 of 12
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loaded and AO-loaded nanospheres was 51.3 ± 14.4%
and 60.3 ± 21.3%, respectively (Figure 1C).
Additionally, larger aggregates were apparent in samples
containing PEG-PEI-AO that were not seen in samples
prepared without PEG-PEI-AO (data not shown). While
these particles were easily filtered out with a 1 μm syringe
filter, the size distribution of the filtered sample remained
remarkably non-uniform. A potential explanation for the
increase in nanosphere size is that PEG-PEI copolymers,
while introduced into the primary aqueous phase, are also
soluble in the organic phase and thus can become incor-
porated within it, or on the surface of the nanospheres.
The amine groups of surface bound PEG-PEI copolymers
can interact with carboxylic acid groups on the nano-
sphere surface, and may act as an electrostatic crosslinker
between nanospheres that induces particle aggregation.
In an effort to obtain smaller mean particle sizes, studies
were carried out to examine the influence of PVA concentra-
tion, sonication intensity, and sonication volume on the size
of unloaded PLGA nanospheres. Pilot studies showed that at
a given sonication intensity, the mean nanosphere size was
decreased up to 30 nm by increasing the concentration of
PVA (w/v) from 2 to 10% (data not shown), an observation
that has been seen in previous studies. However, mass yield
decreased by nearly 20% at both 8 and 10% PVA concentra-
tions, negating any small advantage that would be obtained
by the decrease in size. Thus, 5% PVA concentration was cho-
sen for all subsequent experiments.
Next, we compared the influence of sonication energy on
size distribution of unloaded PLGA nanospheres. We
found that mean size was reduced by increasing sonication
energy from 38 W to a maximum of 51 W, producing nano-
spheres with mean sizes of 309.7 ± 13.2 nm and 241.8 ±
20.2 nm, respectively (Figure 2A). We further reasoned that
sonication in smaller vessels may enhance the energy dissi-
pation into the system. Thus, we also compared the size dis-
tribution of nanospheres formed by sonication in low and
high volume chambers. We found that splitting the second-
ary emulsion into three 20 ml glass scintillation vials con-
taining about 8.3 mL of solution each, sonicating at 52 W,
and recombining the solutions, produced nanospheres
with markedly reduced diameters (154.8 ± 16.4 nm). The
size distributions of the samples are demonstrated to be
more uniform with increased sonication intensity and
Release kinetics of PEG-PEI-AO polyplex from PLGA nanospheresFigur 5
Release kinetics of PEG-PEI-AO polyplex from PLGA nanospheres. Nanospheres were formulated with PLGA poly-
mers with molecular weights of 50 kDa (full line), and 17 kDa (broken line). Measurements were repeated in triplicate for each 
group.Page 7 of 12
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peak widths (calculated as 144 nm, 107 nm, and 95 nm for
38 W high volume sonication, 52 W high volume sonica-
tion, and 52 W low volume sonication, respectively).
Importantly, this improved protocol also facilitated forma-
tion of smaller (206.9 ± 42.9 nm) and more uniform PLGA
nanospheres when loaded with PEG-PEI-AO polyplex com-
pared to the original protocol (Figure 3). Therefore, the
lower volume chamber and higher intensity sonication
were used for all subsequent experiments.
The next step was to evaluate the influence of the PLGA
composition on the nanocapsule properties. We selected
lower molecular weight non-endcapped PLGA composi-
tions (50 kDa and 17 kDa) that we expected to have faster
degradation rates. Unloaded nanospheres showed mean
sizes of 154.8 ± 16.4 nm, 162.5 ± 19.5 nm, and 160.1 ±
16.6 nm, for the 72 kDa, 50 kDa, and 17 kDa PLGA poly-
mers, respectively (Figure 4A). Nanospheres loaded with
PEG-PEI-AO showed mean sizes of 206.9 ± 42.9 nm,
241.7 ± 18.7 nm, and 231.0 ± 21.4 nm, for 72 kDa, 50
kDa, and 17 kDa PLGA, respectively (Figure 4A). Overall,
whether loaded or unloaded, there were no significant dif-
ferences in nanosphere size between the three different
MW PLGA polymers that were investigated (P > 0.05).
However, PLGA nanospheres loaded with PEG-PEI-AO
were about 33–44% larger than un-loaded PLGA.
The surface charge of the PLGA nanospheres was evalu-
ated by measuring zeta potential in dilute PBS. As
expected, unloaded nanospheres formulated using lauryl
ester end-capped 72 kDa PLGA showed the lowest zeta
potential (-17.0 ± 1.4 mV) compared to non end-capped
Dystrophin induction in TA muscles of mdx mice 3 weeks after intramusc lar i jections of AO uwith and without poly-mer car iersFigu e 6
Dystrophin induction in TA muscles of mdx mice 3 
weeks after intramuscular injections of AO uwith and 
without polymer carriers. Muscles were injected on days 
0, 3, and 6 and harvested at 3 weeks after the initial injection. 
Dystrophin immunolabeling of TA muscle cross-sections at 
two different magnifications and H&E staining of serial sec-
tions are shown for (a-a") normal, (b-b") mdx untreated, (c-
c") mdx injected with AO alone, (d-d") mdx injected with 
PEG-PEI-AO polyplex, and (e-e") mdx injected with PLGA 
(17 kDa) nanospheres encapsulated with the PEG-PEI-AO 
polyplex.
Comparison of the number of dystrophin-positive fibers in TA muscles of mdx mice at 3 weeks after 3 intramuscular injection  f PEG-PEI-AO polyplex and PLGA (17 kDa) na o-sphere  encapsulated with the PEG-PEI-AO polyplexFigu e 7
Comparison of the number of dystrophin-positive fib-
ers in TA muscles of mdx mice at 3 weeks after 3 
intramuscular injections of PEG-PEI-AO polyplex and 
PLGA (17 kDa) nanospheres encapsulated with the 
PEG-PEI-AO polyplex. Results are also shown for injec-
tions of AO alone and untreated mdx muscles which are 
known to contain a small number of revertant fibers. All 
treated muscles were given 5 μg AO per injection. Both PLGA 
encapsulated polyplex and unencapsulated polyplex showed a 
significantly higher number of dystrophin positive fibers com-
pared to AO alone injected or untreated mdx muscle (*P < 
0.05). No statistical difference in dystrophin positive fibers was 
observed between untreated muscle and AO alone injected 
groups. Fiber counts were determined from four independ-
ently treated muscles in each group (N = 4).Page 8 of 12
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kDa PLGA (-24.4 ± 1.1 mV) (Figure 4B), with significant
differences between all three groups (P < 0.05). Although
statistically significant, the influence of ester end-capping
on zeta potential was surprisingly small. This may be due
to hydrolysis of the PLGA chains during the solvent evap-
oration step, causing exposure of more carboxylic acid
end groups.
The zeta potential of 50 kDa and 72 kDa PLGA nano-
spheres that were encapsulated with PEG-PEI-AO poly-
plexes was -20.1 ± 1.0 mV and -22.8 ± 1.8 mV, respectively,
which was not significantly different than the respective un-
encapsulated nanospheres (P > 0.05). However, the load-
ing of PEG-PEI-AO polyplexes into endcapped 72 kDA
PLGA nanospheres resulted in a marked neutralization of
the zeta potential (-12.0 ± 0.8 mV; Figure 4B). The amelio-
ration of the surface charge may be due to excess un-encap-
sulated cationic PEG-PEI-AO adsorbed to the surface of the
nanospheres during the formulation procedure. Non-end-
capped PLGA polymers appear to encapsulate polyplexes
within the polymer matrix with a much greater efficiency
than ester end-capped PLGA (see below), which may elim-
inate surface adsorption of PEG-PEI-AO.
As shown in Figure 4C the EE for 72 kDa PLGA was only
about 57.6 ± 7.6%, which was significantly less than for
both 50 kDa PLGA (103.8 ± 7.8%) and 17 kDa PLGA (93.3
± 1.5%) (P < 0.01). On the other hand, the nanosphere
yield for the 72 kDa PLGA preparation was moderately, but
significantly, greater than for the 50 kDa PLGA and 17 kDa
PLGA (P < 0.05) (Figure 4D). The higher level of entrap-
ment is most likely attributed to interaction between car-
boxylic acid end groups on the PLGA interacting with
amine groups on the PEG-PEI. This idea is supported by De
Rosa et al [39,49] who showed significantly higher EE of
oligonucleotides within PLGA microspheres in the pres-
ence of PEI. The increased level of AO entrapment in the
nanospheres highlights another advantage of using PEG-
PEI in PLGA formulations. Due to the low AO encapsula-
tion efficiency within nanospheres formulated using lauryl
ester end-capped PLGA, the following release kinetic stud-
ies and in vivo evaluation of the PEG-PEI-AO nanospheres
focused on formulations using non-endcapped PLGA.
The release rate of PEG-PEI-AO from the PLGA nano-
spheres was measured over the course of 26 days. The rate
of AO release increased with decreasing PLGA molecular
weight, giving a cumulative release of only 38.0 ± 2.0% for
50 kDa PLGA, but significantly higher cumulative release
of 66.5 ± 1.0% for the 17 kDa PLGA (P < 0.01) (Figure 5).
The burst release of PEG-PEI-AO from the 17 kDa PLGA
over the first 24 hours was nearly 20% of the total pay-
load, a rate approximately 4 times greater than for the 50
kDa PLGA (5%). Interestingly, pilot experiments showed
almost no release of polyplexes from nanospheres formu-
lated with 72 kDa PLGA (data not shown). The reason for
this is not clear, but we presume that the end-capping and
high molecular weight of the PLGA significantly retarded
the rate of hydrolysis, and therefore AO release.
To assess functionality of the PLGA compounds we uti-
lized a well characterized paradigm of AO-mediated dys-
trophin expression after intramuscular injections in
dystrophic mdx mice. The mdx mouse contains a stop
codon in exon 23 of the dystrophin gene, which results in
production of truncated and non-functional dystrophin,
resulting in a dystrophic phenotype that resembles DMD.
We and others have recently used an AO that causes skip-
ping of dystrophin exon 23 to rescue dystrophin expres-
sion in skeletal muscle fibers of mdx mice after
intramuscular injections [8,24,25,50-52]. Because the
release of PEG-PEI-AO from the 17 kDa PLGA was more
rapid and complete than other PLGAs, we utilized this for-
mulation exclusively in the functional studies.
PLGA nanospheres (17 kDa) loaded with PEG-PEI-AO
were injected into TA muscles of mdx mice on day 0, 3 and
6 using 5 μg of AO per injection, and muscles were har-
vested 3 weeks after the first injection. Immunolabeling of
transverse sections obtained from the mid-portion of TA
muscles revealed that intramuscular injections of PLGA-
PEG-PEI-AO resulted in the appearance of focal regions
Dystrophin expression in a whole transverse section from TA muscle of an mdx mouse after hree intramuscular injec-tions f PEG-PEI-AO encapsulated in PLGA (17 kDa) nano-sphe eFigu e 8
Dystrophin expression in a whole transverse section 
from TA muscle of an mdx mouse after three intra-
muscular injections of PEG-PEI-AO encapsulated in 
PLGA (17 kDa) nanospheres. Dystrophin immunolabe-
ling is shown for the whole transverse section (A) and the 
two boxed regions are shown at higher magnification (B, C).Page 9 of 12
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(Figure 6). On average, muscles treated with PLGA-PEG-
PEI-AO contained significantly more dystrophin-positive
fibers (324.8 ± 71.6) compared to muscles injected with
AO alone (96.4 ± 62.6) or control uninjected mdx muscles
(45 ± 26.9; P < 0.01; Figure 7). Immunolabeling of entire
transverse sections demonstrates that although there were
pockets of densely populated dystrophin-positive fibers,
over 50% of the muscle cross-sections remained devoid of
those fibers, owing to the incomplete diffusion of the
PLGA nanocapsules throughout the muscle (Figure 8).
Together, these data illustrate that PEG-PEI-AO is released
from PLGA nanospheres in vivo and that the AO is able to
maintain functionality, as indicated by induction of dys-
trophin expression.
Intramuscular injections of un-encapsulated PEG-PEI-AO
polyplexes also resulted in improved expression of dys-
trophin-positive fibers (Figure 6), with no significant dif-
ference in the number of dystrophin-positive fibers
between muscles injected with PLGA-PEG-PEI-AO or un-
encapsulated PEG-PEI-AO (P = 0.49; Figure 7). These
results show that this particular formulation of PEG-PEI
copolymer, comprised of high MW PEI (25 kDa) and long
PEG chains (5 kDa) appears to function as a fairly efficient
carrier on its own for delivery of AO to myofibers.
Although not systematically studied, western blots indi-
cated that both PEG-PEI-AO and PLGA-PEG-PEI-AO pro-
duced only about 5–10% of normal levels of dystrophin
expression (data not shown). This was much less than the
20–30% of dystrophin expression we obtained with PEG-
PEI copolymers comprised of low MW PEI (2 kDa)
[24,25], but was still much better than the dystrophin
expression found with AO alone (~0–2% of normal). Fur-
ther studies must be done to evaluate whether encapsula-
tion of PEG-PEI-AO containing low MW PEI2K in PLGA
will perform better than the high MW PEI25K. As dis-
cussed above, the release rate from the 17 kDa PLGA
nanospheres was quite slow, reaching only 60% release
after 3 weeks. We expect that the advantage of encapsulat-
ing PEG-PEI-AO in PLGA may become more significant
when the functionality (dystrophin expression) is meas-
ured over a longer time range. Histological analysis of
muscle morphology did not reveal any overt signs of cyto-
toxicity at 3 weeks after injection, indicating that the
degradable PLGA nanospheres may be suitable for longer
term application to muscles (Figure 6).
Conclusion
In this study, formulation conditions were established for
encapsulating PEG-PEI-AO polyplexes within biodegrada-
ble PLGA nanospheres. Although several previous studies
reported encapsulation of cationic polymers complexed
to nucleic acids within PLGA structures, these studies
focused on relatively large micron-sized PLGA formula-
tions, that limits their usefulness for some in vivo applica-
tions (reviewed in Capan et al. [53]). In the present study,
formulation parameters were chosen to allow for nearly
100% encapsulation efficiency of positively-charged PEG-
PEI-AO polyplexes within PLGA nanospheres (200–300
nm) that shielded the surface charge of the cationic poly-
plexes and showed a surprisingly uniform size distribu-
tion. The PLGA nanospheres exhibited sustained release
of the PEG-PEI-AO polyplexes in solution. Immunohisto-
chemical analysis demonstrated AO-mediated dystrophin
expression 3 weeks after intramuscular injections in mdx
mice of the PLGA-encapsulated PEG-PEI-AO polyplexes.
A drawback to the study is that the dystrophin expression
levels were not improved using encapsulated polyplexes
compared to unencapsulated polyplexes. One reason for
this may be incomplete release of AO at 3 weeks following
injection. This study demonstrated the feasibility of PEG-
PEI-AO encapsulation, however further studies evaluating
dystrophin expression at multiple time points are war-
ranted to fully realize their potential in vivo. To our knowl-
edge, the present study is the first to demonstrate the
feasibility of internalizing PEG-PEI-AO polyplexes within
PLGA nanospheres for in vivo applications. The nanome-
ter size, charge shielding, and controlled release proper-
ties of the PLGA carriers should offer significant
improvement in the biodistribution and sustained deliv-
ery of AO complexed with the PEG-PEI copolymers,
enhancing the utility of this popular carrier for in vivo
usage.
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